Phaseline

Targets › TNFRSF17

TNFRSF17 (Tumor necrosis factor receptor superfamily member 17): drug programs, companies and trials

25 programs from 22 companies in 174 trials: 77 Phase 2, 63 Phase 1, 30 Phase 3, 4 Phase 4; Oncology, Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. (UniProt, Q02223)

Open in Phaseline: the race on TNFRSF17, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johnson & Johnson (Janssen)Ciltacabtagene Autoleucel (JNJ-68284528)
Tumor necrosis factor receptor superfamily member 17 binding agent
TNFRSF17Phase 4Multiple Myeloma; Recurrent Multiple Myeloma; High Risk Smoldering Multiple Myeloma; Relapse Multiple Myeloma …Feb 2027
PfizerElranatamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 4Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma …May 2027
Regeneron PharmaceuticalsLinvoseltamab
anti-B-cell maturation antigen x anti-CD3 bispecific antibody
BCMA, GPRC5D, CD3E, TNFRSF17Phase 4Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) …Aug 2027
GSKBelantamab mafodotin
Tumor necrosis factor receptor superfamily member 17 binding agent; Tubulin inhibitor
TNFRSF17, TubulinPhase 3Multiple Myeloma; Amyloidosis; Plasma Cell Myeloma; Myeloma Multiple …Dec 2026
Johnson & Johnson (Janssen)Teclistamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
Johnson & Johnson (Janssen)JNJ-79635322
Bispecific antibody targeting CD3 and BCMA
CD3E, TNFRSF17Phase 3Multiple Myeloma; Relapsed or Refractory Multiple MyelomaApr 2027
Johnson & Johnson (Janssen)Ramantamig
BCMAxGPRC5DxCD3 trispecific antibody
TNFRSF17, CD3E, BCMA, GPRC5DPhase 3Multiple MyelomaDec 2027
Bristol-Myers Squibbidecabtagene vicleucel
Tumor necrosis factor receptor superfamily member 17 binding agent
TNFRSF17Phase 3Multiple MyelomaNov 2029
Keymed Biosciences Co.LtdCM336
BCMA/CD3 bispecific antibody
BCMA, CD3E, TNFRSF17Phase 2Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous DiseaseDec 2026
Peking University First Hospital68Ga-BCMA
BCMA-targeted PET imaging agent
TNFRSF17Phase 2Multiple MyelomaDec 2027
Peking University People's HospitalBCMA-CD19 CAR-T therapy
Dual-targeted CAR-T cell therapy against BCMA and CD19
TNFRSF17, CD19Phase 2Systemic Lupus ErythematosusDec 2027
iCell Gene TherapeuticsICG318
BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain
TNFRSF17, CD19, BCMAPhase 2Systemic Lupus Erythematosus (SLE); Inflammatory MyopathyDec 2027
PETHEMA FoundationAnitocabtagene Autoleucel
CAR-T cell therapy targeting BCMA
TNFRSF17Phase 2De Novo Multiple MyelomaMar 2028
The First Hospital of Jilin UniversityIL-15-armored BCMA-targeted CAR-T cells
IL-15-armored CAR-T cells targeting BCMA
TNFRSF17, IL15Phase 2Relapsed/Refractory Multiple MyelomaJul 2028
Memorial Sloan Kettering Cancer CenterElranatamab-bcmm
Bispecific antibody targeting BCMA and CD3
TNFRSF17, CD3EPhase 2Multiple MyelomaAug 2029
Multiple Myeloma Research ConsortiumLinvoseltamab
B-cell maturation antigen (BCMA) × CD3 bispecific monoclonal antibody
TNFRSF17, CD3EPhase 2High Risk Newly Diagnosed Multiple MyelomaOct 2035
The First Affiliated Hospital of Soochow UniversityCART-138/BCMA/19/more
Multi-antigen CAR-T cell therapy targeting CD138, BCMA (TNFRSF17), CD19, and additional an
CD138, TNFRSF17, CD19Phase 1Multiple MyelomaDec 2026
Gracell Biotechnologies (Shanghai)GC012F
BCMA/CD19 dual CAR-T cell therapy
TNFRSF17, CD19, BCMAPhase 1Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL AmyloidosisFeb 2027
Beijing BiotechAutologous anti-BCMA CAR-T cells
CAR-T cell therapy targeting BCMA-expressing plasma cells
TNFRSF17Phase 1REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUSMar 2027
Technische Universität DresdenMDC-CAR-BCMA001
BCMA-targeting CAR T-cell therapy
TNFRSF17Phase 1NeoplasmsJun 2027
VyriadVV169
In vivo BCMA-CAR T cell therapy (T-cell targeted lentiviral vector expressing BCMA-directe
TNFRSF17Phase 1Multiple Myeloma RefractoryAug 2027
David AviganBCMA CAR-T
Anti-BCMA CAR-T cell therapy
TNFRSF17Phase 1Multiple MyelomaMar 2028
Medical College of WisconsinBCMA-TGFβ CAR-T cells
BCMA-targeted CAR-T cell therapy with TGF-beta costimulatory domain
TNFRSF17Phase 1Multiple MyelomaMay 2028
Chongqing Precision BiotechBCMA/CD70 CAR-T cells
Dual-targeted CAR-T cell therapy against BCMA and CD70
TNFRSF17, CD70Phase 1Systemic Lupus ErythematosusAug 2028
AstraZenecaAZD4045
Allogeneic CAR-T cell therapy targeting BCMA (B cell maturation antigen)
TNFRSF17Phase 1Relapsed or Refractory Multiple MyelomaMar 2031

Conditions

Multiple Myeloma (96) Recurrent Multiple Myeloma (6) Relapsed Refractory Multiple Myeloma (RRMM) (5) AL Amyloidosis (5) Relapsed/Refractory Multiple Myeloma (4) Multiple Myeloma, Newly Diagnosed (3) Myeloma (3) Multiple Myeloma (MM) (3) Relapsed or Refractory Multiple Myeloma (2) Relapse Multiple Myeloma (2) Refractory Multiple Myeloma (2) Plasma Cell Myeloma (2)

Modalities

mixed (13), other (6), protein or peptide (3), antibody (1), small molecule (1)

Companies

Johnson & Johnson (Janssen) (4) Regeneron Pharmaceuticals (1) AstraZeneca (1) David Avigan (1) Pfizer (1) GSK (1) Peking University People's Hospital (1) Gracell Biotechnologies (Shanghai) (1) Technische Universität Dresden (1) Bristol-Myers Squibb (1) Keymed Biosciences Co.Ltd (1) The First Hospital of Jilin University (1) The First Affiliated Hospital of Soochow University (1) Medical College of Wisconsin (1) Chongqing Precision Biotech (1) iCell Gene Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Peking University First Hospital (1) Multiple Myeloma Research Consortium (1) Beijing Biotech (1)

Related targets

CD3E (8) BCMA (5) CD19 (4) GPRC5D (2) CD3G (2) CD3D (2) Tubulin (1) IL15 (1) CD138 (1) CD70 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.